Polen Capital Management LLC Purchases 1,323 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Polen Capital Management LLC lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 26.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,328 shares of the medical research company’s stock after purchasing an additional 1,323 shares during the period. Polen Capital Management LLC’s holdings in Charles River Laboratories International were worth $1,496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of CRL. VisionPoint Advisory Group LLC raised its stake in Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at approximately $37,000. Operose Advisors LLC bought a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $42,000. Brown Brothers Harriman & Co. lifted its holdings in shares of Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after buying an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter worth $62,000. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CRL shares. TD Cowen reduced their price target on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a report on Monday, May 13th. Evercore ISI boosted their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research report on Thursday, February 15th. The Goldman Sachs Group began coverage on Charles River Laboratories International in a research note on Thursday, June 6th. They set a “buy” rating and a $290.00 price target for the company. Argus lifted their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, UBS Group increased their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $256.38.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the sale, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 1.4 %

NYSE CRL traded down $2.97 on Friday, hitting $209.47. 407,102 shares of the stock were exchanged, compared to its average volume of 551,956. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The firm has a market capitalization of $10.79 billion, a P/E ratio of 24.64, a P/E/G ratio of 2.02 and a beta of 1.40. The stock has a fifty day moving average price of $227.31 and a two-hundred day moving average price of $231.81.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Research analysts forecast that Charles River Laboratories International, Inc. will post 11 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).